Aurinia Pharmaceuticals Inc (AUPH)

[puravida]

I think I need to revise my estimate of what Pharma would pay for AUPH considering the margins that VOC has and the 2037 patent timeline peak sales potential Ive been low balling the valuation While I don't see AUPH selling for 13-15B (I'd take it) Im intrigued about BMY's 13B deal for Myocardia. Mavacamten wasn't even approved at the time of the merger and seems to have a similar sales ramp as Lupkynis (peak 1-2B annual sales) under its protected patents. Mycocardia also had other earlier stage assets as well (danicamtiv) perhaps helping the deal get that high. But still one can't rule out a 10B takeout for aurinia tho I have typically concluded that was also on the unlikely side so $45-60 a share from $35-42 range